| Title |
Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: a randomized controlled trial
|
|---|---|
| Published in |
Acta Diabetologica, August 2018
|
| DOI | 10.1007/s00592-018-1204-1 |
| Pubmed ID | |
| Authors |
Luciana Neves Cosenso-Martin, Luiz Tadeu Giollo-Júnior, Letícia Aparecida Barufi Fernandes, Cláudia Bernardi Cesarino, Marcelo Arruda Nakazone, Maurício de Nassau Machado, Juan Carlos Yugar-Toledo, José Fernando Vilela-Martin |
| Abstract |
Several trials have reported that dipeptidyl peptidase-4 (DPP-4) inhibitors, used to treat type 2 diabetes (T2DM), improve endothelial function. The current study investigated the effects of vildagliptin, a DPP-4 inhibitor, compared to glibenclamide on endothelial function, arterial stiffness, and blood pressure in patients with T2DM and hypertension. Patients aged over 35 years with T2DM and hypertension, but without cardiovascular disease, were randomly allocated to treatment with vildagliptin (n = 25) or glibenclamide (n = 25). Both groups took metformin. Endothelial function was evaluated by peripheral artery tonometry (Endo-PAT 2000) to calculate the reactive hyperemia index (RHI) and arterial stiffness. Primary outcome was change in the RHI after 12 weeks of treatment. Twenty-four-hour non-invasive ambulatory blood pressure monitoring was performed using a Mobil-O-Graph® 24-h PWA monitor. Arterial stiffness was assessed using the augmentation index corrected for 75 bpm (AIx75), pulse wave velocity (PWV) and central systolic blood pressure (cSBP). There were no changes in the RHI in the vildagliptin group (before 2.35 ± 0.59; after 2.24 ± 0.60; p value = NS) or in the glibenclamide group (before 2.36 ± 0.52; after 2.34 ± 0.50; p value = NS), with no differences between groups (p value = NS). There was also no difference between vildagliptin and glibenclamide treatment in respect to AIx75 (p value = NS), cSBP (p value = NS) or PWV (p value = NS). Vildagliptin and glibenclamide similarly do not change the endothelial function and arterial stiffness after 12 weeks of treatment in diabetic and hypertensive patients without cardiovascular disease. Thus, vildagliptin has a neutral effect on vascular function. ClinicalTrials.gov: NCT02145611, registered on 11 Jun 2013. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Chile | 1 | 25% |
| Spain | 1 | 25% |
| Canada | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 25% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 74 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 15% |
| Other | 9 | 12% |
| Student > Bachelor | 6 | 8% |
| Student > Master | 6 | 8% |
| Student > Postgraduate | 5 | 7% |
| Other | 13 | 18% |
| Unknown | 24 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 23% |
| Nursing and Health Professions | 6 | 8% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Engineering | 3 | 4% |
| Other | 11 | 15% |
| Unknown | 29 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 August 2018.
All research outputs
#15,016,514
of 23,099,576 outputs
Outputs from Acta Diabetologica
#514
of 932 outputs
Outputs of similar age
#198,800
of 331,391 outputs
Outputs of similar age from Acta Diabetologica
#11
of 29 outputs
Altmetric has tracked 23,099,576 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 932 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,391 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.